D. E. Shaw & Co., Inc. Ligand Pharmaceuticals Inc Call Options Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2021 Nov 15, 2021	SELL	$102.33 - $144.73 $1.02 Million - $1.45 Million	-10,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$99.52 - $215.83 $2.64 Million - $5.72 Million	-26,500 Reduced 72.6%	10,000 $1.53 Million
Q3 2019 Nov 14, 2019	SELL	$86.25 - $120.16 $1.73 Million - $2.4 Million	-20,000 Reduced 35.4%	36,500 $3.63 Million
Q2 2019 Aug 14, 2019	BUY	$107.38 - $129.34 $5.55 Million - $6.69 Million	51,700 Added 1077.08%	56,500 $6.45 Million
Q1 2019 May 15, 2019	SELL	$105.93 - $142.47 $730,917 - $983,043	-6,900 Reduced 58.97%	4,800 $603,000
Q4 2018 Feb 14, 2019	SELL	$128.36 - $272.13 $2.27 Million - $4.82 Million	-17,700 Reduced 60.2%	11,700 $1.59 Million
Q3 2018 Nov 14, 2018	BUY	$211.18 - $274.49 $2.47 Million - $3.21 Million	11,700 Added 66.1%	29,400 $8.07 Million
Q2 2018 Aug 14, 2018	BUY	$150.77 - $207.98 $1.16 Million - $1.6 Million	7,700 Added 77.0%	17,700 $3.67 Million
Q4 2017 Feb 14, 2018	BUY	$128.36 - $147.04 $1.28 Million - $1.47 Million	10,000	10,000 $1.37 Million

255

18.1M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.79B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.